Drug Trial Radar · NCT03361865
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
93
Actual
Start
Dec 4, 2017
Primary completion
Aug 9, 2018
Study completion Aug 4, 2020
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Dec 5, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo in participants with cisplatin-ineligible urothelial carcinoma.
Conditions
- UC (Urothelial Cancer)
Interventions
PembrolizumabDrug
Pembrolizumab administered intravenously every 3 weeks.
EpacadostatDrug
Epacadostat administered orally twice daily.
PlaceboDrug
Matching placebo administered orally twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) With Pembrolizumab + Epacadostat Versus Pembrolizumab + PlaceboTime frame: Week 9
Locations
143 sites in 18 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates PC- HOPE
Tucson, Arizona
University of California Irvine Medical Center
Orange, California
Yale Cancer Center
New Haven, Connecticut
Woodlands Medical Specialists, PA
Pensacola, Florida
Rush University Medical Center
Chicago, Illinois
Quincy Medical Group
Quincy, Illinois
Massachusetts General Hospital
Boston, Massachusetts
GU Research Network-Urology Cancer Center
Omaha, Nebraska
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Medical University of South Carolina-Hollings Cancer Center
Charleston, South Carolina
Tennessee Oncology, PLLC/The Sarah Cannon Research Institute
Chattanooga, Tennessee
University of Tennessee Medical Center Knoxville
Knoxville, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee
Tennessee Oncology Nashville
Nashville, Tennessee
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
Texas Oncology-Memorial City
Houston, Texas
University of Washington
Seattle, Washington
Adelaide Cancer Centre
Kurralta Park, Australia
Macquarie University Hospital
Macquarie Park, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Southern Medical Day Care Centre
Wollongong, New South Wales, Australia
Austin Health-Austin Hospital
Heidelberg, Victoria, Australia
Institut Jules Bordet
Brussels, Belgium
Grand Hopital de Charleroi - Site Notre Dame - Oncology
Charleroi, Belgium
AZ Maria Middelares Gent
Ghent, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Hopital de Jolimont
Haine-Saint-Paul, Belgium
AZ Nikolaas
Sint-Niklaas, Belgium
GZA Sint Augustinus
Wilrijk, Belgium
Moncton Hospital - Horizon Health Network
Moncton, New Brunswick, Canada
Cancer Centre of Southeastern Ontario at Kingston General Hospital
Kingston, Ontario, Canada
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Sunnybrook Health Science Centre
Toronto, Ontario, Canada
CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont
Montreal, Quebec, Canada
CHU de Quebec - Hotel-Dieu de Quebec
Québec, Quebec, Canada
Showing 40 of 143 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.